|
|
Article: Sirtris Raises $37M Through Series C Fund Raising, Debt.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
As it shifts its focus from discovery and preclinical testing to early clinical development, 2-year-old Sirtris Pharmaceuticals Inc. raised $22 million in a Series C round and secured another $15 million through a debt placement.
The Cambridge, Mass.-based company, founded in spring 2004, plans to bring its lead sirtuin therapeutics into human studies with the funds.
"The use of the proceeds is to help the company move into clinical trials in one to two indications by the end of this year or early next year," said Sirtris' CEO and co-founder Christoph Westphal.
The company focuses on seven human sirtuins that could ...
Related newspaper, magazine, and journal articles:
|
|
Article: Norwest Venture Partners Invests Additional $2 ...
Business Wire;
October 14, 1998 ;
700+ words
...PALO ALTO, Calif.--(BUSINESS ... 1998--Norwest Venture Partners, the premier ... investors. Norwest Venture Partners has now invested ... partner with Norwest Venture Partners serves on the ... in San Ramon, Calif., plans to use ...
|
|